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Abstract Here we investigated a biological association of con-
stitutively active Src with TrkA in SK-N-MC human neuroblas-
toma cells. Activation of TrkA and extracellular signal-regu-
lated kinase (ERK) by nerve growth factor (NGF) was
inhibited by pretreatment with PP2, an inhibitor of Src family
kinases. Moreover, NGF-induced phosphorylation of TrkA and
ERK was also attenuated by the transfection with a dominant-
negative src construct. On the other hand, the transfection with
a constitutively active src construct enhanced these phosphory-
lations. In addition, we showed that active Src phosphorylates
TrkA directly in vitro, and that Src associates with TrkA
through Grb2 after NGF stimulation. These results suggest
that constitutively active Src that associates with TrkA through
Grb2 after NGF stimulation participates in TrkA phosphoryla-
tion and in turn enhances the mitogen-activated protein kinase
signaling in SK-N-MC cells.
- 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Src, a non-receptor protein tyrosine kinase, is over-ex-
pressed and highly activated in a variety of human cancers
including those of the colon, breast, pancreas, and brain [1].
Such an altered Src appears to have an important role in the
development, growth, progression and metastasis of these can-
cers [1,2]. However, the mechanism of Src contribution to the
cancer phenotype is not yet known although activated Src has
been shown to activate a number of signaling proteins and
lead to cell transformation [3^6].
Src has been reported to associate with several receptor
tyrosine kinases (RTKs), such as epidermal growth factor
receptor (EGFR), platelet-derived growth factor receptor
(PDGFR), vascular endothelial growth factor receptor and
glial cell line-derived neurotrophic factor receptor [7^10]. Par-
ticularly, the activation of EGFR by over-expressed Src is
intriguing because of biological synergy for mitogenesis in
¢broblasts [7]. Moreover, the mutation of PDGFR at
Tyr934, phosphorylated by Src, leads to a decrease in mito-
genesis in porcine aortic endothelial cells [8]. These results
have suggested the possibility that the activation of RTKs
by altered Src might contribute to facilitate the malignant
progression.
TrkA, a principal receptor of nerve growth factor (NGF), is
one of the RTKs [11]. The binding of NGF to TrkA promotes
growth, di¡erentiation and survival of several neural cells [11^
13]. Recently, Src has been shown to associate with TrkA. Lee
et al. [14] demonstrated that the pituitary adenylate cyclase-
activating polypeptide, a neuropeptide that acts through G
protein-coupled receptors, induces the phosphorylation of
TrkA in PC12 pheochromocytoma cells. This phosphorylation
of TrkA depends on Src activity, and does not require NGF
binding. Moreover, Wooten et al. [15] showed that TrkA is
detected in Src immunoprecipitates, which were obtained
from PC12 cell lysates in response to NGF treatment. These
results have led us to hypothesize that altered Src might acti-
vate TrkA and enhance the signaling that could contribute to
neuronal cell transformation. In the present study, we there-
fore investigated whether highly activated Src has in£uence in
the activation of TrkA and its downstream signaling event in
neuroblastoma.
To test this, we have used SK-N-MC human neuroblasto-
ma cells that express a high level of constitutively active Src.
In addition, we observed the expression of TrkA in these cells.
Therefore, SK-N-MC cells could be useful to investigate the
interaction between activated Src and TrkA. We demonstrate
that the constitutively active Src facilitates NGF-induced
phosphorylation of TrkA, causing enhancement of the mito-
gen-activated protein kinase (MAPK) signaling.
2. Materials and methods
2.1. Reagents and antibodies
Dulbecco’s modi¢ed Eagle’s medium (DMEM) and dimethyl sulf-
oxide (DMSO) were purchased from Sigma (St. Louis, MO, USA).
Trypsin-EDTA, penicillin/streptomycin and Lipofectamine1 2000
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were from Invitrogen (Grand Island, NY, USA). Fetal bovine serum
(FBS) was from Cansera International (Ontario, Canada). Isogen and
Gene Taq polymerase chain reaction (PCR) reagents were from Nip-
pon Gene (Tokyo, Japan). Human L-NGF was obtained from Alo-
mone (London, UK). K252a, AG879, PP2, PP3 and U0126 were
obtained from Calbiochem (Torrance, CA, USA). Anti-TrkA (763),
anti-Trk (C-14), anti-extracellular signal-regulated kinase 1 (ERK1)
(K-23), anti-phospho-ERK (E-4), anti-Grb2 (C-23) antibodies, and
horseradish peroxidase-conjugated goat antibodies to rabbit or mouse
IgG were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-phospho-TrkA (Tyr490) and anti-phospho-Src family
(Tyr416) antibodies were obtained from Cell Signaling Technology
(Beverly, MA, USA). Anti-Src and anti-p75NTR antibodies, active
Src, Src kinase reaction bu¡er and Src manganese/ATP cocktail
were from Upstate Biotechnology (Waltham, MA, USA). The First-
strand cDNA synthesis kit, protein G-Sepharose, the ECL detection
reagent and X-ray ¢lm were obtained from Amersham Biosciences
(Piscataway, NY, USA).
2.2. Cell culture
Human neuroblastoma SK-N-MC cells (HTB-10; ATCC) and hu-
man neuroblastoma SH-SY5Y cells (CRL-2266; ATCC) were cul-
tured in DMEM supplemented with 10% FBS and 1% penicillin/strep-
tomycin, 5% CO2 at 37‡C.
2.3. Reverse transcription (RT) PCR
Total RNA (1.5 Wg) was isolated from SH-SY5Y and SK-N-MC
cells using Isogen. After reverse transcription using the First-strand
cDNA synthesis kit, cDNA was ampli¢ed with Gene Taq PCR re-
agents. For RT-PCR, the following primers were used: TrkA (Gen-
Bank accession number (GBN): M23102), 5P-TCTTCACTGAGT-
TCCTGGAG-3P and 5P-TTCTCCACCGGGTCTCCAGA-3P ; TrkB
(GBN: S76473), 5P-TACATCTGTACTAAAATACA-3P and 5P-GT-
GTCCCCGATGTCATTCGC-3P ; TrkC (GBN: S76475), 5P-CATCC-
ATGTGGAATACTACC-3P and 5P-TGGGTCACAGTGATAGGA-
GG-3P ; L-actin (GBN: NM_001101), 5P-CCCATGCCATCCTGCG-
TCTG-3P and 5P-CGTCATACTCCTGCTTGCTG-3P. The PCR was
performed as follows: after 94‡C for 4 min for denaturing cDNA, 35
cycles of 94‡C for 1 min, 60‡C for 1 min, 72‡C for 1 min, and a ¢nal
extension at 72‡C for 10 min in an automated thermal cycler (Bio-Rad
Laboratories). 10 Wl of each PCR product was run onto a 2.5% aga-
rose gel and visualized with ethidium bromide.
TrkA primers amplify two fragments of 229 and 247 bp corre-
sponding to two alternatively spliced trkA transcripts [16]. TrkB,
TrkC and L-actin primers amplify fragments of 515, 543 and 570
bp, respectively.
2.4. Cell treatments, lysis, immunoprecipitation, and Western blotting
SK-N-MC and SH-SY5Y cells (1U106) were seeded in 35-mm tis-
sue culture dish (Falcon) and cultured for 3 days. Cells were washed
twice with serum-free DMEM and then starved in fresh DMEM with-
out serum for 6 h prior to NGF stimulation. Each culture was incu-
bated with either AG879, K252a, U0126, PP2, PP3, or DMSO (as
control) for 20 min before adding NGF.
Cells were washed with cold phosphate-bu¡ered saline (PBS) and
solubilized in Nonidet P-40 lysis bu¡er (20 mM Tris^HCl, pH 7.5, 150
mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 mM EGTA, 0.1 mM
phenylmethylsulfonyl £uoride, 1 mM Na3VO4 and 1% protease inhib-
itor cocktail).
Precleared cell lysates (1 mg) were incubated with either 2 Wg of
anti-Trk (C-14) or 4 Wg of anti-Src antibody for 16 h at 4‡C. Then,
immune complexes were precipitated with protein G-Sepharose for 2 h
at 4‡C.
Whole cell lysates (20 Wg or 50 Wg for analysis for TrkA) and
immunoprecipitates were separated by 7.5 or 10% sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and then
electroblotted onto polyvinylidene £uoride membranes (Immune-
Blot PVDF membrane; Bio-Rad Laboratories). The membranes
were blocked using 5% non-fat dried milk in PBS, pH 7.2, and pri-
mary immunoreactions were performed with anti-ERK1 (1:4000),
anti-phospho-ERK (1:2000), anti-Grb2 (1:1000) and anti-p75NTR
(1:1000) antibodies for 1 h at room temperature or with anti-TrkA
(1:1000), anti-phospho-TrkA (1:1000), anti-Src (1:1000) and anti-
phospho-Src (1:1000) antibodies for 18 h at 4‡C. The membranes
were washed three times with TBST bu¡er (20 mM Tris^HCl, pH
7.4, 150 mM NaCl, 0.1% Tween 20) and then incubated with second-
ary antibodies (horseradish peroxidase-conjugated goat antibodies to
rabbit or mouse IgG) (1:2000) for 1 h at room temperature. The
membranes were washed three times with TBST bu¡er and developed
using an ECL detection reagent prior to exposure to an X-ray ¢lm.
2.5. Transient transfection
SK-N-MC cells were grown to 80% con£uence in 35-mm tissue
culture dishes. The culture medium was replaced with 2 ml of fresh
DMEM supplemented with 10% FBS and the cells were further cul-
tured for another 24 h. A mixture containing 3 Wg of an expression
vector containing src cDNA mutant (dominant-negative src K296R/
Y528F or constitutively active src Y529F; Upstate Biotechnology)
and 10 Wl of Lipofectamine1 2000 reagents was carefully added to
each culture and incubated in 5% CO2 at 37‡C for 48 h. The trans-
fection e⁄ciency was veri¢ed by Western blot analysis of Src expres-
sion.
2.6. In vitro Src kinase assay
TrkA was prepared by immunoprecipitation with 2 Wg of anti-Trk
antibody for 16 h at 4‡C from 2 mg of SK-N-MC cell lysates. TrkA
immunoprecipitates were incubated for 10 min at 30‡C in reaction mix
containing 10 Wl of active Src, 10 Wl of Src kinase reaction bu¡er and
10 Wl of Src manganese/ATP cocktail. The reaction was stopped with
the addition of Laemmli sample bu¡er.
3. Results and discussion
3.1. Expression of constitutively active Src and neurotrophin
receptors in SH-SY5Y and SK-N-MC cells
We selected a useful neuroblastoma cell line for studying
the interaction between constitutively active Src and TrkA.
SH-SY5Y cells appear to express activated Src and neurotro-
phin receptors, including TrkA, TrB, TrkC and p75NTR [17^
19]. On the other hand, it has been reported that SK-N-MC
cells that express activated Src also express p75NTR [17,20].
We veri¢ed the expression of constitutively active Src and
neurotrophin receptors in these neuroblastoma cells by RT-
PCR and Western blotting. SH-SY5Y cells express protein
level of TrkA and constitutively active Src, which was dem-
onstrated by the phosphorylation of Src at Tyr416 [21,22]
(Fig. 1B). In addition, RT-PCR products for TrkA, TrkB
and TrkC were detected in these cells (Fig. 1A). Similarly,
SK-N-MC cells express constitutively active Src and neuro-
trophin receptors except for TrkC (Fig. 1A,B). In contrast to
a previous report that showed SK-N-MC cells express p75NTR
but not TrkA [20], we could detect both receptors in these
cells. A high level of p75NTR expression was detected in SK-
N-MC cells. However, the expression of TrkA was su⁄cient
to investigate a signaling event via this receptor.
The expression level of constitutively active Src in SK-N-
MC cells was higher than that in SH-SY5Y cells although
both cells express equal levels of TrkA. These results
prompted us to investigate the biological association of acti-
vated Src with TrkA in SK-N-MC cells.
3.2. NGF-induced signaling in SK-N-MC cells
The binding of NGF to TrkA activates its cytoplasmic ki-
nase, resulting in autophosphorylation of speci¢c tyrosine res-
idues within the intracellular domain [4,5]. Phosphorylated
tyrosines serve as protein interaction sites for several signaling
molecules, such as Shc, phospholipase CQ, FRS-2 and SH2-B,
and activate several de¢ned signaling cascades, including Raf/
ERK and phosphatidylinositol 3-kinase/Akt [13]. Therefore,
we investigated whether these signaling pathways are acti-
vated after NGF stimulation in SK-N-MC cells.
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Exposure of serum-starved SK-N-MC cells to NGF in-
duced the phosphorylation of TrkA, which peaked 3 min after
NGF stimulation and then declined (Fig. 2A). We also ob-
served a transient phosphorylation of ERK1/2, which lasted
1^10 min after NGF stimulation (Fig. 2A). The NGF-induced
phosphorylation of TrkA and ERK1/2 was enhanced in a
dose-dependent manner (Fig. 2B). In contrast, phospho-Akt
was undetectable (data not shown).
The NGF-induced phosphorylation of ERK1/2 was com-
pletely blocked by pretreatment with 30 WM U0126 that in-
hibits the ERK upstream kinase MAPK kinase [23] (Fig. 2C).
Moreover, ERK phosphorylation was also inhibited by 30
WM AG879 and 200 nM K252a, inhibitors of TrkA phosphor-
ylation [24,25] (Fig. 2C). These results suggest that NGF ac-
tivates the MAPK pathway via TrkA in SK-N-MC cells.
3.3. Participation of constitutively active Src in NGF-induced
signal transduction
To clarify the involvement of constitutively active Src in
NGF-induced signal transduction, we investigated the inhibi-
tory e¡ect of PP2, a selective inhibitor of Src family kinases
(SFKs) [26]. As shown in Fig. 3, PP2 but not PP3 (negative
control) decreased the amount of phospho-Src (Tyr416) in a
Fig. 2. NGF-induced signaling in SK-N-MC cells. SK-N-MC cells
were starved for 6 h and then treated with NGF. A: Time course
of NGF-induced phosphorylation of TrkA and ERK. Cells were
treated with 100 ng/ml NGF and lysed at the indicated time. B:
Dose response of NGF-induced phosphorylation of TrkA and
ERK. Cells were incubated in the presence of NGF at the indicated
concentration for 3 min prior to cell lysis. C: Inhibition of NGF-in-
duced ERK phosphorylation by treatment with inhibitors of TrkA
and ERK phosphorylations. Cells were preincubated in the presence
of 30 WM AG879, 200 nM K252a and 30 WM U0126 for 20 min,
and stimulated with 100 ng/ml NGF for 3 min. TrkA and ERK ac-
tivations were analyzed by Western blotting with anti-phospho-
TrkA (Tyr490) and anti-phospho-ERK antibodies, respectively.
After stripping, TrkA and ERK expressions were veri¢ed by reprob-
ing the same blots with anti-TrkA and anti-ERK1 antibodies (lower
panels). The positions of phosphorylated p42ERK2 and p44ERK1 are
shown.
Fig. 1. Expression of constitutively active Src and neurotrophin re-
ceptors in SH-SY5Y and SK-N-MC cells. A: RT-PCR analysis of
neurotrophin receptors. Total RNA from SH-SY5Y and SK-N-MC
cells was extracted and reverse-transcribed to cDNA. PCR was per-
formed using gene-speci¢c primers for TrkA, TrkB and TrkC with
L-actin as a control (see Section 2). B: Western blot analysis of
TrkA, p75NTR and constitutively active Src (p-Src). Cells were lysed,
and then total lysates were resolved by SDS^PAGE and probed
with anti-TrkA, anti-p75NTR, anti-phospho-Src (Tyr416) and anti-
Src antibodies.
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dose-dependent manner suggesting that PP2 inhibits Src ac-
tivity. Pretreatment of SK-N-MC cells with PP2 attenuated
NGF-induced phosphorylation of TrkA and ERK1/2.
PP2 has been reported to be a selective inhibitor of SFKs
[26]. However, to rule out the possibility that PP2 might di-
rectly inhibit the phosphorylation of TrkA and ERK, we
veri¢ed the Src activity inhibition by the transfection with a
dominant-negative src construct. The transfection with the
dominant-negative src construct allows for the expression of
mutant Src (K297R/Y528F), which appears without phospho-
tyrosine activity in the presence of normal binding activity of
adapter proteins [27,28]. Consistent with the e¡ect of PP2, the
transfection with the dominant-negative src construct inhib-
ited NGF-induced phosphorylation of TrkA and ERK1/2
when compared with cells transfected with the empty vector
(Fig. 4A). In addition, the transfection with a constitutively
active src construct enhanced NGF-induced phosphorylation
of TrkA and ERK1/2 (Fig. 4B).
In an in vitro Src kinase assay, TrkA was phosphorylated
by active Src directly (Fig. 5). Src also appears to activate
ERK by phosphorylating signaling molecules, such as Shc
or focal adhesion kinase (FAK), generating binding sites for
Grb2 [29]. In SK-N-MC cells, however, these signaling mole-
cules would be little a¡ected by constitutively active Src be-
cause the phosphorylation of ERK is detected only at a low
level in the absence of NGF stimulation. Moreover, there was
no change in the expression of phospho-Src (Tyr416) under
NGF stimulation conditions (Fig. 3), supporting the possibil-
ity that constitutively active Src also did not a¡ect the signal-
ing molecules in the presence of NGF stimulation. Thus, our
results suggest that constitutively active Src contributes partly
to phosphorylation of TrkA, resulting in enhancement of
MAPK signaling in SK-N-MC cells.
3.4. Association of Src with TrkA
We investigated the association of Src with TrkA. In anti-
Src or anti-Trk immunoprecipitation study, co-immunopreci-
pitates of Src with TrkA were not detected in the absence or
presence of NGF stimulation (Fig. 6). Moreover, constitu-
tively active Src had little e¡ect on TrkA phosphorylation in
the absence of NGF stimulation (Fig. 3). These results have
led us to hypothesize that the association of Src with TrkA
may be mediated by adapter molecules that associate with
both TrkA and Src.
Fig. 3. Inhibition of NGF-induced phosphorylation of TrkA and
ERK by pretreatment with PP2, a SFK inhibitor. SK-N-MC cells
were serum-starved for 6 h. Cells were preincubated in the presence
of PP2 or PP3 at the indicated concentration for 20 min, and stimu-
lated with 100 ng/ml NGF for 3 min. Cells were lysed, and then
TrkA, ERK and Src activations were analyzed by Western blotting
with anti-phospho-TrkA (Tyr490), anti-phospho-ERK and anti-
phospho-Src (Tyr416) antibodies, respectively. After stripping, load-
ing of equal amounts of TrkA, ERK and Src was veri¢ed by re-
probing the same blots with anti-TrkA, anti-ERK1 and anti-Src
antibodies (lower panels).
Fig. 4. E¡ect of dominant-negative Src or over-expressed constitu-
tively active Src on NGF-induced phosphorylation of TrkA and
ERK. SK-N-MC cells were transiently transfected with a dominant-
negative src construct (A) or a constitutively active src construct (B)
by a Lipofectamine method as described in Section 2. Transfected
cells were starved in DMEM without serum for 6 h, and stimulated
with 100 ng/ml NGF for 3 min. Cells were lysed, and then TrkA
and ERK activations were assessed by Western blotting with anti-
phospho-TrkA (Tyr490) and anti-phospho-ERK antibodies, respec-
tively. After stripping, loading of equal amounts of TrkA and ERK
was veri¢ed by reprobing the same blots with anti-TrkA and anti-
ERK1 antibodies (lower panels). The transfection e⁄ciency was
veri¢ed by Western blotting with anti-Src antibody.
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Grb2 has been reported to associate with TrkA or FAK, a
SFK [30,31]. Therefore, we investigated the link between Grb2
and TrkA or Src. Analysis of anti-Trk or anti-Src immuno-
precipitates indicated that Grb2 is co-immunoprecipitated
with both TrkA and Src (Fig. 6). The amount of co-immuno-
precipitates of Grb2 with Src was not a¡ected by NGF stim-
ulation. On the other hand, the amount of co-immunopreci-
pitates of Grb2 with TrkA was found to be increased by NGF
stimulation. These results suggest that constitutively active Src
associates with TrkA through Grb2 after NGF stimulation.
Although Shc also appears to associate with both TrkA and
Src [32,33], co-immunoprecipitates of Shc with Src were not
detected in SK-N-MC cell lysates (data not shown).
In conclusion, our results suggest that constitutively active
Src that associates with TrkA through Grb2 after NGF stim-
ulation facilitates phosphorylation of TrkA and in turn acti-
vates the MAPK pathway. Src can increase the transcription
of cyclin D1 in NIH3T3 and MCF7 cells [34,35]. This e¡ect of
Src requires activation of MAPK signaling. Src-activated
MAPK signaling also induces Rat-1 cells to enter the S phase
of the cell cycle [36]. Moreover, the cells that express consti-
tutively active MAPK kinase have been reported to form
transformed foci, grow e⁄ciently in soft agar, and be highly
tumorigenic in nude mice [37]. These results suggest that
MAPK signaling plays an important role in cell transforma-
tion. Therefore, the enhancement of MAPK signaling medi-
ated by interaction between altered Src and TrkA may con-
tribute to neuronal cell transformation.
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